Beyond the Big Tech Platform Wars: The Fringe Economy from AI Cooling to Nuclear FusionGlobal Report·Jul 22 at 04:18 AMZYME-2.65%TT-4.94%
Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026 | ZYME Stock NewsStockTitan·Jul 15 at 09:00 PMTBPH-0.24%ZYME-2.65%
Major Theravance Biopharma Investor Makes Notable Stock MoveTip Ranks·Jul 8 at 09:02 PMTBPH-0.24%ZYME-2.65%
Zymeworks Earns Buy Rating as Non-Dilutive Theravance Deal and Long-Duration YUPELRI Cash Flows Drive Price Target Up to $37Tip Ranks·Jun 30 at 04:55 AMZYME-2.65%TBPH-0.24%
Zymeworks agrees to buy Theravance Biopharma for $929mPharmaceutical Business Review·Jun 30 at 03:00 AMTBPH-0.24%ZYME-2.65%
Zymeworks Inc. Stock 12‑Month Price Target Raised to $38.75, Implies 60% UpsideTradingView·Jun 29 at 05:20 PMZYME-2.65%
Zymeworks to acquire Theravance Biopharma for USD 17 per share in USD 929 million dealPUBT·Jun 29 at 05:00 AMTBPH-0.24%ZYME-2.65%
13:36 ET$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Theravance Biopharma, Inc. (NASDAQ: TBPH)prnewswire·Jun 29 at 12:37 PMTBPH-0.24%ZYME-2.65%
10:02 ETShareholder Alert: Ademi LLP investigates whether Theravance Biopharma, Inc. is obtaining a Fair Price for Public Shareholdersprnewswire·Jun 29 at 09:03 AMTBPH-0.24%ZYME-2.65%
Zymeworks’ TBPH Acquisition Seen as Cash-Flow Accretive, Supports Buy Rating and Unchanged $34 Price TargetTip Ranks·Jun 29 at 09:55 AMZYME-2.65%TBPH-0.24%
